Certain Strontium-Rubidium Radioisotope Infusion Systems, and Components Thereof Including Generators; Institution of Investigation, 19112-19113 [2018-09068]

Download as PDF amozie on DSK30RV082PROD with NOTICES 19112 Federal Register / Vol. 83, No. 84 / Tuesday, May 1, 2018 / Notices (a) Production (quantity) and, if known, an estimate of the percentage of total production of Subject Merchandise in the Subject Country accounted for by your firm’s(s’) production; (b) Capacity (quantity) of your firm(s) to produce the Subject Merchandise in the Subject Country (that is, the level of production that your establishment(s) could reasonably have expected to attain during the year, assuming normal operating conditions (using equipment and machinery in place and ready to operate), normal operating levels (hours per week/weeks per year), time for downtime, maintenance, repair, and cleanup, and a typical or representative product mix); and (c) the quantity and value of your firm’s(s’) exports to the United States of Subject Merchandise and, if known, an estimate of the percentage of total exports to the United States of Subject Merchandise from the Subject Country accounted for by your firm’s(s’) exports. (12) Identify significant changes, if any, in the supply and demand conditions or business cycle for the Domestic Like Product that have occurred in the United States or in the market for the Subject Merchandise in the Subject Country after 2012, and significant changes, if any, that are likely to occur within a reasonably foreseeable time. Supply conditions to consider include technology; production methods; development efforts; ability to increase production (including the shift of production facilities used for other products and the use, cost, or availability of major inputs into production); and factors related to the ability to shift supply among different national markets (including barriers to importation in foreign markets or changes in market demand abroad). Demand conditions to consider include end uses and applications; the existence and availability of substitute products; and the level of competition among the Domestic Like Product produced in the United States, Subject Merchandise produced in the Subject Country, and such merchandise from other countries. (13) (OPTIONAL) A statement of whether you agree with the above definitions of the Domestic Like Product and Domestic Industry; if you disagree with either or both of these definitions, please explain why and provide alternative definitions. Authority: This proceeding is being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.61 of the Commission’s rules. By order of the Commission. VerDate Sep<11>2014 18:12 Apr 30, 2018 Jkt 244001 Issued: April 23, 2018. Lisa Barton, Secretary to the Commission. [FR Doc. 2018–08793 Filed 4–30–18; 8:45 am] BILLING CODE 7020–02–P INTERNATIONAL TRADE COMMISSION [Investigation No. 337–TA–1110] Certain Strontium-Rubidium Radioisotope Infusion Systems, and Components Thereof Including Generators; Institution of Investigation U.S. International Trade Commission ACTION: Notice. AGENCY: Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on March 27, 2018, under section 337 of the Tariff Act of 1930, as amended, on behalf of Bracco Diagnostics Inc. of Monroe Township, New Jersey. An amended complaint was filed on April 13, 2018. The amended complaint alleges violations of section 337 based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain strontiumrubidium radioisotope infusion systems, and components thereof including generators by reason of infringement of U.S. Patent No. 9,814,826 (‘‘the ’826 patent’’); U.S. Patent No. 9,750,869 (‘‘the ’869 patent’’); and U.S. Patent No. 9,750,870 (‘‘the ’870 patent’’). The amended complaint further alleges that an industry in the United States exists as required by the applicable Federal Statute. The complainant requests that the Commission institute an investigation and, after the investigation, issue a limited exclusion order and cease and desist orders. ADDRESSES: The complaint, except for any confidential information contained therein, is available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW, Room 112, Washington, DC 20436, telephone (202) 205–2000. Hearing impaired individuals are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at (202) 205– 2000. General information concerning SUMMARY: PO 00000 Frm 00074 Fmt 4703 Sfmt 4703 the Commission may also be obtained by accessing its internet server at https://www.usitc.gov. The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS) at https://edis.usitc.gov. FOR FURTHER INFORMATION CONTACT: Pathenia M. Proctor, The Office of Unfair Import Investigations, U.S. International Trade Commission, telephone (202) 205–2560. SUPPLEMENTARY INFORMATION: Authority: The authority for institution of this investigation is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337 and in section 210.10 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.10 (2018). Scope of Investigation: Having considered the complaint, the U.S. International Trade Commission, on April 24, 2018, ordered that— (1) Pursuant to subsection (b) of section 337 of the Tariff Act of 1930, as amended, an investigation be instituted to determine whether there is a violation of subsection (a)(1)(B) of section 337 in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain strontiumrubidium radioisotope infusion systems, and components thereof including generators by reason of infringement of one or more of claims 1–3, 5, 9–14, 17– 19, 26, and 28 of the ’826 patent; claims 1–5, 8, 14, 24, and 27–30 of the ’869 patent; and claims 1, 2, 8–13, 16, 17, 22, and 27 of the ’870 patent; and whether an industry in the United States exists, or is in the process of being established, as required by subsection (a)(2) of section 337; (2) Pursuant to Commission Rule 210.50(b)(1), 19 CFR 210.50(b)(1), the presiding administrative law judge shall take evidence or other information and hear arguments from the parties and other interested persons with respect to the public interest in this investigation, as appropriate, and provide the Commission with findings of fact and a recommended determination on this issue, which shall be limited to the statutory public interest factors set forth in 19 U.S.C. 1337(d)(1), (f)(1), (g)(1); (3) For the purpose of the investigation so instituted, the following are hereby named as parties upon which this notice of investigation shall be served: (a) The complainant is: Bracco Diagnostics Inc., 259 Prospect Plains Road, Building H, Monroe Township, NJ 08831. (b) The respondents are the following entities alleged to be in violation of E:\FR\FM\01MYN1.SGM 01MYN1 Federal Register / Vol. 83, No. 84 / Tuesday, May 1, 2018 / Notices section 337, and are the parties upon which the complaint is to be served: amozie on DSK30RV082PROD with NOTICES (c) The Office of Unfair Import Investigations, U.S. International Trade Commission, 500 E Street SW, Suite 401, Washington, DC 20436; and (4) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge. Responses to the complaint and the notice of investigation must be submitted by the named respondents in accordance with section 210.13 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(e) and 210.13(a), such responses will be considered by the Commission if received not later than 20 days after the date of service by the Commission of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown. Failure of a respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent. By order of the Commission. Issued: April 25, 2018. Lisa Barton, Secretary to the Commission. [FR Doc. 2018–09068 Filed 4–30–18; 8:45 am] BILLING CODE 7020–02–P VerDate Sep<11>2014 18:12 Apr 30, 2018 Jkt 244001 AGENCY: particularly with respect to the estimated public burden or associated response time, have suggestions, need a copy of the proposed information collection instrument with instructions, or desire any other additional information, please contact Nicole Timmons either by mail at CG–3, 10th Floor, Washington, DC 20530–0001, by email at Nicole.Timmons@usdoj.gov, or by telephone at 202–236–2646. Written comments and/or suggestions can also be directed to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503 or sent to OIRA_ submissions@omb.eop.gov. SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Evaluate whether and if so how the quality, utility, and clarity of the information to be collected can be enhanced; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. The Department of Justice (DOJ), U.S. Marshals Service (USMS), will submit the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection was previously published in the Federal Register on January 17, 2018, allowing for a 60-day comment period. DATES: Comments are encouraged and will be accepted for an additional 30 days until May 31, 2018. FOR FURTHER INFORMATION CONTACT: If you have additional comments, Overview of This Information Collection (1) Type of Information Collection: New collection. (2) The Title of the Form/Collection: Form CSO–005, Preliminary Background Check Form. (3) The agency form number, if any, and the applicable component of the Department sponsoring the collection: Form number: CSO–005. Component: U.S. Marshals Service, U.S. Department of Justice. (4) Affected public who will be asked or required to respond, as well as a brief abstract: Primary: Court Security Officers/ Special Security Officer (CSO/SSO) Applicants. DEPARTMENT OF JUSTICE Jubilant DraxImage Inc., 16751 TransCanada Highway, Kirkland, ´ Quebec, Canada, H9H 4J4 Jubilant Pharma Limited, 6 Temasek Boulevard, #20–06 Suntec City, Tower Four, Singapore 038986 Jubilant Life Sciences, Plot 1–A Sector 16–A Institutional Area, Noida, Uttar Pradesh, 201301 India 19113 Foreign Claims Settlement Commission [F.C.S.C. Meeting and Hearing Notice No. 5–18] Sunshine Act Meeting The Foreign Claims Settlement Commission, pursuant to its regulations (45 CFR part 503.25) and the Government in the Sunshine Act (5 U.S.C. 552b), hereby gives notice in regard to the scheduling of open meetings as follows: Thursday, May 10, 2018: 10:00 a.m.— Issuance of Proposed Decisions in claims against Iraq. Status: Open. All meetings are held at the Foreign Claims Settlement Commission, 601 D Street NW, Suite 10300, Washington, DC. Requests for information, or advance notices of intention to observe an open meeting, may be directed to: Patricia M. Hall, Foreign Claims Settlement Commission, 601 D Street NW, Suite 10300, Washington, DC 20579. Telephone: (202) 616–6975. Brian M. Simkin, Chief Counsel. [FR Doc. 2018–09098 Filed 4–26–18; 11:15 am] BILLING CODE 4410–BA–P DEPARTMENT OF JUSTICE U.S. Marshals Service [OMB Number 1105—NEW] Agency Information Collection Activities; Proposed eCollection eComments Requested; Proposed Collection; Comments Requested: Form CSO–005, Preliminary Background Check Form U.S. Marshals Service, Department of Justice. ACTION: 30-Day notice. SUMMARY: PO 00000 Frm 00075 Fmt 4703 Sfmt 4703 E:\FR\FM\01MYN1.SGM 01MYN1

Agencies

[Federal Register Volume 83, Number 84 (Tuesday, May 1, 2018)]
[Notices]
[Pages 19112-19113]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-09068]


-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1110]


Certain Strontium-Rubidium Radioisotope Infusion Systems, and 
Components Thereof Including Generators; Institution of Investigation

AGENCY: U.S. International Trade Commission

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that a complaint was filed with the 
U.S. International Trade Commission on March 27, 2018, under section 
337 of the Tariff Act of 1930, as amended, on behalf of Bracco 
Diagnostics Inc. of Monroe Township, New Jersey. An amended complaint 
was filed on April 13, 2018. The amended complaint alleges violations 
of section 337 based upon the importation into the United States, the 
sale for importation, and the sale within the United States after 
importation of certain strontium-rubidium radioisotope infusion 
systems, and components thereof including generators by reason of 
infringement of U.S. Patent No. 9,814,826 (``the '826 patent''); U.S. 
Patent No. 9,750,869 (``the '869 patent''); and U.S. Patent No. 
9,750,870 (``the '870 patent''). The amended complaint further alleges 
that an industry in the United States exists as required by the 
applicable Federal Statute.
    The complainant requests that the Commission institute an 
investigation and, after the investigation, issue a limited exclusion 
order and cease and desist orders.

ADDRESSES: The complaint, except for any confidential information 
contained therein, is available for inspection during official business 
hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. 
International Trade Commission, 500 E Street SW, Room 112, Washington, 
DC 20436, telephone (202) 205-2000. Hearing impaired individuals are 
advised that information on this matter can be obtained by contacting 
the Commission's TDD terminal on (202) 205-1810. Persons with mobility 
impairments who will need special assistance in gaining access to the 
Commission should contact the Office of the Secretary at (202) 205-
2000. General information concerning the Commission may also be 
obtained by accessing its internet server at https://www.usitc.gov. The 
public record for this investigation may be viewed on the Commission's 
electronic docket (EDIS) at https://edis.usitc.gov.

FOR FURTHER INFORMATION CONTACT: Pathenia M. Proctor, The Office of 
Unfair Import Investigations, U.S. International Trade Commission, 
telephone (202) 205-2560.

SUPPLEMENTARY INFORMATION:

    Authority: The authority for institution of this investigation 
is contained in section 337 of the Tariff Act of 1930, as amended, 
19 U.S.C. 1337 and in section 210.10 of the Commission's Rules of 
Practice and Procedure, 19 CFR 210.10 (2018).

    Scope of Investigation: Having considered the complaint, the U.S. 
International Trade Commission, on April 24, 2018, ordered that--
    (1) Pursuant to subsection (b) of section 337 of the Tariff Act of 
1930, as amended, an investigation be instituted to determine whether 
there is a violation of subsection (a)(1)(B) of section 337 in the 
importation into the United States, the sale for importation, or the 
sale within the United States after importation of certain strontium-
rubidium radioisotope infusion systems, and components thereof 
including generators by reason of infringement of one or more of claims 
1-3, 5, 9-14, 17-19, 26, and 28 of the '826 patent; claims 1-5, 8, 14, 
24, and 27-30 of the '869 patent; and claims 1, 2, 8-13, 16, 17, 22, 
and 27 of the '870 patent; and whether an industry in the United States 
exists, or is in the process of being established, as required by 
subsection (a)(2) of section 337;
    (2) Pursuant to Commission Rule 210.50(b)(1), 19 CFR 210.50(b)(1), 
the presiding administrative law judge shall take evidence or other 
information and hear arguments from the parties and other interested 
persons with respect to the public interest in this investigation, as 
appropriate, and provide the Commission with findings of fact and a 
recommended determination on this issue, which shall be limited to the 
statutory public interest factors set forth in 19 U.S.C. 1337(d)(1), 
(f)(1), (g)(1);
    (3) For the purpose of the investigation so instituted, the 
following are hereby named as parties upon which this notice of 
investigation shall be served:
    (a) The complainant is: Bracco Diagnostics Inc., 259 Prospect 
Plains Road, Building H, Monroe Township, NJ 08831.
    (b) The respondents are the following entities alleged to be in 
violation of

[[Page 19113]]

section 337, and are the parties upon which the complaint is to be 
served:

Jubilant DraxImage Inc., 16751 TransCanada Highway, Kirkland, 
Qu[eacute]bec, Canada, H9H 4J4
Jubilant Pharma Limited, 6 Temasek Boulevard, #20-06 Suntec City, Tower 
Four, Singapore 038986
Jubilant Life Sciences, Plot 1-A Sector 16-A Institutional Area, Noida, 
Uttar Pradesh, 201301 India

    (c) The Office of Unfair Import Investigations, U.S. International 
Trade Commission, 500 E Street SW, Suite 401, Washington, DC 20436; and
    (4) For the investigation so instituted, the Chief Administrative 
Law Judge, U.S. International Trade Commission, shall designate the 
presiding Administrative Law Judge.
    Responses to the complaint and the notice of investigation must be 
submitted by the named respondents in accordance with section 210.13 of 
the Commission's Rules of Practice and Procedure, 19 CFR 210.13. 
Pursuant to 19 CFR 201.16(e) and 210.13(a), such responses will be 
considered by the Commission if received not later than 20 days after 
the date of service by the Commission of the complaint and the notice 
of investigation. Extensions of time for submitting responses to the 
complaint and the notice of investigation will not be granted unless 
good cause therefor is shown.
    Failure of a respondent to file a timely response to each 
allegation in the complaint and in this notice may be deemed to 
constitute a waiver of the right to appear and contest the allegations 
of the complaint and this notice, and to authorize the administrative 
law judge and the Commission, without further notice to the respondent, 
to find the facts to be as alleged in the complaint and this notice and 
to enter an initial determination and a final determination containing 
such findings, and may result in the issuance of an exclusion order or 
a cease and desist order or both directed against the respondent.

    By order of the Commission.

    Issued: April 25, 2018.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2018-09068 Filed 4-30-18; 8:45 am]
BILLING CODE 7020-02-P